CA2658263A1 - Thiadiazolidinone derivatives - Google Patents

Thiadiazolidinone derivatives Download PDF

Info

Publication number
CA2658263A1
CA2658263A1 CA002658263A CA2658263A CA2658263A1 CA 2658263 A1 CA2658263 A1 CA 2658263A1 CA 002658263 A CA002658263 A CA 002658263A CA 2658263 A CA2658263 A CA 2658263A CA 2658263 A1 CA2658263 A1 CA 2658263A1
Authority
CA
Canada
Prior art keywords
leukemia
subject
compound
cells
pkc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002658263A
Other languages
English (en)
French (fr)
Inventor
Craig Jordan
Monica Guzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2658263A1 publication Critical patent/CA2658263A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002658263A 2006-07-18 2007-07-18 Thiadiazolidinone derivatives Abandoned CA2658263A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83189306P 2006-07-18 2006-07-18
US60/831,893 2006-07-18
PCT/US2007/016391 WO2008011113A2 (en) 2006-07-18 2007-07-18 Thiadiazolidinone derivatives

Publications (1)

Publication Number Publication Date
CA2658263A1 true CA2658263A1 (en) 2008-01-24

Family

ID=38957376

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002658263A Abandoned CA2658263A1 (en) 2006-07-18 2007-07-18 Thiadiazolidinone derivatives

Country Status (7)

Country Link
US (2) US9180118B2 (enExample)
EP (1) EP2043633B1 (enExample)
JP (1) JP2009543874A (enExample)
AU (1) AU2007275686B2 (enExample)
CA (1) CA2658263A1 (enExample)
NZ (1) NZ574619A (enExample)
WO (1) WO2008011113A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer
US20090117090A1 (en) * 2007-11-01 2009-05-07 Ottawa Heart Institute Research Corporation Inhibition of glycogen synthase kinase 3 beta in arterial repair and stent re-endothelialization
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
MX388409B (es) * 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
WO2016149464A1 (en) 2015-03-17 2016-09-22 Regeneron Pharmaceuticals, Inc. Amino acid acylation reagents and methods of using the same
EP3484477B1 (en) * 2016-07-14 2023-09-13 Mingsight Pharmaceuticals, Inc. Treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11335298A (ja) * 1997-12-16 1999-12-07 Sankyo Co Ltd 白血病治療剤
AU1507799A (en) 1997-12-16 1999-07-05 Sankyo Company Limited Leukemia remedy
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
FI20041129A0 (fi) * 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
US20060204980A1 (en) * 2004-12-28 2006-09-14 Altieri Dario C Colorectal cancer therapies
US20070196514A1 (en) * 2006-02-21 2007-08-23 Benyi Li Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer

Also Published As

Publication number Publication date
US20100063109A1 (en) 2010-03-11
US20160058741A1 (en) 2016-03-03
WO2008011113A2 (en) 2008-01-24
EP2043633A4 (en) 2009-11-25
EP2043633B1 (en) 2016-07-06
WO2008011113A3 (en) 2008-02-28
EP2043633A2 (en) 2009-04-08
US9180118B2 (en) 2015-11-10
AU2007275686B2 (en) 2013-10-31
AU2007275686A1 (en) 2008-01-24
NZ574619A (en) 2012-03-30
JP2009543874A (ja) 2009-12-10

Similar Documents

Publication Publication Date Title
US20160058741A1 (en) Thiadiazolidinone Derivatives
JP5204761B2 (ja) ピリミジンジアミン化合物を使用することによる細胞増殖性障害を処置する方法
CA2846496C (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP5827962B2 (ja) Ｃｄｃ７キナーゼ阻害剤およびその使用
Chen et al. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
US12551482B2 (en) Aurora kinase inhibitors
CN111757731B (zh) 三取代苯并三唑衍生物的使用方法
EP2763998B1 (en) Tri-heterocyclic derivatives, preparation process and uses thereof
US11384076B2 (en) Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors
US10759803B2 (en) Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
EP3512602B1 (en) Inhibitors of heat shock factors (hsf) and uses thereof
WO2016196991A1 (en) Therapeutic targeting of myeloproliferative neoplasms by dusp1 inhibition
TW202033191A (zh) 新穎藥物組成物及其用途
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
JP2023550049A (ja) Ｉｒｅ１アルファ阻害剤及びその使用
AU2020267382B2 (en) Compositions and methods for treating cancer
US20180305330A1 (en) Materials and method for inhibiting replication protein a and uses thereof
RU2746705C2 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
Padrón Carrillo et al. Click-chemistry mediated synthesis of OTBN-1, 2, 3-Triazole derivatives exhibiting STK33 inhibition with diverse anti-cancer activities
CN101198253A (zh) 治疗癌症的组合、方法和组合物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20150119